Tetyana Pertseva
#77,301
Most Influential Person Now
Ukrainian physician and academic administrator
Tetyana Pertseva's AcademicInfluence.com Rankings
Tetyana Pertsevabusiness Degrees
Business
#1316
World Rank
#1502
Historical Rank
Management
#630
World Rank
#714
Historical Rank
Tetyana Pertsevaphilosophy Degrees
Philosophy
#13086
World Rank
#18369
Historical Rank
Logic
#10211
World Rank
#13068
Historical Rank
Download Badge
Business Philosophy
Why Is Tetyana Pertseva Influential?
(Suggest an Edit or Addition)According to Wikipedia, Tetyana Oleksiivna Pertseva is a Ukrainian pulmonologist, physician-scientist, and academic administrator. She is the rector of the Dnipro State Medical University and editor-in-chief of Medičnì Perspektivi. Pertseva is an elected academician of the National Academy of Sciences of Ukraine.
Tetyana Pertseva's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. (2013) (49)
- Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial (2013) (26)
- Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations (2016) (25)
- Results from the Survey of Antibiotic Resistance (SOAR) 2014–16 in Ukraine and the Slovak Republic (2018) (10)
- Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Ukraine. (2016) (10)
- ADAPTED CLINICAL GUIDELINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Part 1) (2019) (5)
- ADAPTED CLINICAL GUIDELINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2020) (5)
- Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma (2012) (4)
- Influence of tobacco-smoking on serum level of transforming growth factor (TGF) beta 1 in COPD patients (2017) (4)
- Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. (2020) (4)
- Influence of tiotropium bromide (TB) and carbocysteine (C) on mucociliary clearance (MCC) in patients with COPD (2012) (4)
- Systemic inflammation in patients with chronic obstructive pulmonary disease (2013) (3)
- European screening for α1-antitrypsin deficiency in subjects with lung disease (2012) (3)
- Bronchoectatic disease: the state of art and the clinical case. (2018) (2)
- Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts) (2016) (2)
- ADAPTED EVIDENCE-BASED CLINICAL GUIDELINES: BRONCHIAL ASTHMA(Part 1) (2020) (2)
- Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Ukraine and the Slovak Republic. (2018) (2)
- Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program (2014) (2)
- Diagnostic role of systemic inflammation, blood coagulation and padua prediction score in lung thrombosis risk estimation in hospitalized patients with community-acquired pneumonia. (2019) (2)
- Plasma surfactant protein D (SP-D) and smoking status in healthy persons (2014) (2)
- Community-aquired pneumonia on the background of coronaviral disease (COVID-19): principles of diagnostics and determination of risk factors of pathological process aggravation (2020) (2)
- Clinical, general, hemocoagulation and pathologicanatomical features of patients with moderate and severe community acquired pneumonia by the data of retrospective analysis. (2017) (1)
- The comparative characteristic of respiratory muscles function in patients with bronchial obstruction (2011) (1)
- Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level (2014) (1)
- Dynamic changes of markers of endothelial function, hemostasis, fibrinolysis and inflammation in hospitalized patients with community-acquired pneumonia (2019) (1)
- Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity (2017) (1)
- Relevant approaches to modernization of academic and material and technical process support of academic process in the field of knowledge “Health care” in terms of adapting to international assessment criteria. (2019) (1)
- Surfactant Protein D And C-Reactive Protein in patients with lower respiratory tract infections (2014) (1)
- VENTILATION AND DIFFUSIONAL DISORDERS IN PERSONS AFTER COMMUNITYACQUIRED PNEUMONIA, ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19). POSSIBILITIES OF INHALATION THERAPY (2021) (1)
- Difficult diagnosis. Clinical analysis of pneumonia overdiagnosis case. (2013) (1)
- Influence of insulin resistance on renal function in patients with abdominal obesity. (2015) (1)
- Allergic bronchopulmonary aspergillosis: XXI century. A modern view on the problem (2018) (1)
- The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) (2014) (1)
- ADAPTED CLINICAL GUIDELINES: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Part 2) (2019) (1)
- Forecasting thrombotic complications in patients with community acquired pneumonia according to multidimensional analysis of severity, systematic inflammation, endothelial function and hemostasis (2021) (1)
- COPD as undetected cause of dyspnea in patients admitted with ischaemic heart disease (IHD) (2014) (1)
- Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? (2015) (1)
- The prevalence of antimicrobial resistance of P. aeruginosa, K. pneumoniae, E. coli, A. baumanii in Ukraine (2014) (1)
- Lymphocyte-to-monocyte ratio (LMR) as a predictor of Covid-19 pneumonia progression (2021) (1)
- CD4 as a predictor of systemic inflammatory response and death at severe community-acquired pneumonia (2013) (1)
- Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD (2012) (1)
- Comparison of diagnostic value of patient health questionnaire 9 (PHQ-9) and Beck depression inventory (BDI) questionnaire for preliminary diagnosing of depression in COPD patients (pts) (2014) (1)
- Quantitative morphological characteristics of platelet hemostasis in patients with type 1 and 2 diabetes mellitus depending on the glomerular filtration rate. (2018) (1)
- Possible predictors of depressive syndrome in patients with chronic obstructive pulmonary disease. (2018) (1)
- COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level (2015) (1)
- ADAPTED EVIDENCE-BASED CLINICAL GUIDELINES: BRONCHIAL ASTHMA (PART 3) (2021) (1)
- The general practitioners knowledge and educational programs efficiency in antibiotic use (2012) (1)
- Comparison of severity of clinical, functional signs of COPD with the frequency and severity of mental disorders (2017) (0)
- Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) (2013) (0)
- Special aspects and challenges of diagnosis of depressive disorders in patients with chronic obstructive pulmonary disease (2014) (0)
- Doxofylline: Efficacy and safety in complex treatment of COPD (2011) (0)
- Serum albumin and probability of pleural effusion in patients with community-acquired pneumonia (2013) (0)
- Peculiarities of mental status in patients with chronic obstructive pulmonary disease in different phases of the pathological process. (2016) (0)
- What are the best spirometric predictors of COPD progression? (2022) (0)
- Can procalcitonin (PCT) be an indicator of viral severe community-acquired pneumonia (CAP) based on epidemics of influenza H1N1in season 2015-2016? (2016) (0)
- CAP in pregnant: the connection between inflammatory biomarkers and efficacy of antibacterial treatment (2015) (0)
- Features of etiology and pathogen identification in patients with severe community acquired pneumonia (2014) (0)
- Clinical and laboratory predictors of survival in patients with severe community-acquired pneumonia (CAP) (2014) (0)
- HEALTH RELATED QUALITY OF LIFE (HRQoL) AMONG PATIENTS WITH NON CYSTIC FIBROSIS BROCHIECTASIS (BE) IN STABLE PHASE (2018) (0)
- A NEW PERSPECTIVE ON BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP: POTENTIAL DIAGNOSTIC CRITERIA (2020) (0)
- Endothelial dysfunction and its corrections in patients with severe community-aquired pneumonia (CAP) (2020) (0)
- The bronchial asthma course change during pregnancy (2012) (0)
- Lymphocyte-to-Monocyte ratio (LMR) and Platelet-to-lymphocyte (PLR) ratio levels as a predictors of lung failure in severe Covid-19 pneumonia patients (pts) (2021) (0)
- What is the best biomarker of COVID-19 pneumonia progression? (2021) (0)
- Impact of systemic inflammation on frequency and severityof mental disorders in COPD patients (pts) (2020) (0)
- Chronic diseases of the respiratory system during pregnancy. Approaches to diagnosis and treatment (2015) (0)
- Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI) (2013) (0)
- Fenspiride as complementary anti-inflammatory agent in therapy of patients with chronic obstructive pulmonary disease (2011) (0)
- Peculiarities of climacteric syndrome in women with bronchial asthma, developed in the perimenopausal period, correction of these disorders (2015) (0)
- Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease (2013) (0)
- Platelet-vessel wall interaction component and coagulation component of hemostasis in patients with chronic obstructive pulmonary disease (2014) (0)
- THE FORECAST OF LETHAL OUTCOME IN CHRONIC LEUKEMIA PATIENTS WITH PNEUMONIA. (2019) (0)
- Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? (2015) (0)
- Gender differences in formation of endothelial dysfunction (ED) extension in COPD patients (2011) (0)
- New view at the problem of COPD with bronchial asthma (A) (2019) (0)
- Features of resistance of major pathogens of respiratory tract infections in Dnipropetrovsk region. (2014) (0)
- Influence the phosphatidylcholine treatment program on surfactant protein D levels in hypertensive patients with community-acquired pneumonia (2018) (0)
- Fibrinogen like the predictor of COVID-19 pneumonia progression (2021) (0)
- Mental disorders in patients (pts) with COVID-19 pneumonia:comparison with COPD exacerbation (2021) (0)
- Severity, risk of progression or thrombosis – what does the D-dimer really reflect in COVID-19 pneumonia? (2021) (0)
- Vascular-platelet hemostasis parameters in the stable phase and in acute exacerbation (AE) of COPD (2015) (0)
- Serum surfactant protein D (SPD) as a specific marker for COPD (2012) (0)
- THE RELATIONSHIP BETWEEN BIOMARKERS OF SYSTEMIC INFLAMMATION AND SEVERITY IN STABLE COPD. (2019) (0)
- The effectiveness and necessity of carrying out etiological diagnostics in patients with lower respiratory tract infections (2014) (0)
- Thrombotic disorders (blood coagulation test and Padua Prediction Score for risk of lung thrombosis)in hospitalized patients with community-acquired pneumonia (CAP) (2018) (0)
- Peculiarities of sex hormonal status and incidence of osteoporosis in perimenopausal asthmatic women (2013) (0)
- THE ROLE OF PROTEIN C IN HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (2019) (0)
- Immune and inflammatory predictors of survival in patients with severe community-acquired pneumonia (2014) (0)
- ASTHMA IN PATIENTS WITH BRONCHIECTASIS: FEATURES OF THE PHENOTYPE (2020) (0)
- C-reactive protein (CRP) at admission: is it really usefull in COVID-19 pneumonia? (2021) (0)
- ISTH Criteria for Disseminated Intravascular Coagulation (DIC) scale, Padua scale, D-dimer or Fibrinogen: what is the best predictor of COVID-19 pneumonia progression? (2021) (0)
- Impact of the phosphatidylcholine treatment program on the surfactant protein D levels in hypertensive patients with Acute Exacerbations of COPD (2020) (0)
- Proteinase-inhibitor system state in patients with COPD (2015) (0)
- The best coagulation marker for prediction of COVID-19 pneumonia progression (2021) (0)
- Procalcitonin as etiological marker of severe community-acquired pneumonia (2013) (0)
- Detection of chronic obstructive pulmonary disease (COPD) in patients with cardio-vascular system pathology (2013) (0)
- THE ROLE OF QUALITY OF INGALATION OF MEDICINAL PRODUCT BY COPD PATIENTS IN MODERN REALITIES (2020) (0)
- MODERN VIEW OF ASTHMA: FOCUS ON THE GINA GUIDELINES (2020) (2020) (0)
- Prediction of violations of primary and secondary hemostasis in patients with chronic obstructive pulmonary disease (2018) (0)
- Are there serum levels of MMP-2 and MMP-9 may be markers of COPD phenotypes? (2012) (0)
- Changes in bronchial mucous membrane depending on the stage of COPD (I, II) (2011) (0)
- Effects of nebivolol and ivabradine on myocardial ischemia in patients (pts) with COPD and stable angina during 24-hour ambulatory Holter ECG monitoring (2017) (0)
- Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes (2015) (0)
- P361 The relation of medics to vaccination against an influenza virus (2013) (0)
- On relationship between local and systemic chronic inflammation and between level of hypoxia and bronchial obstruction in COPD pts (2013) (0)
- Severity or risk of progression: what does serum ferritin really reflect in COVID-19 pneumonia? (2021) (0)
- ADAPTED EVIDENCE-BASED CLINICAL GUIDELINES: BRONCHIAL ASTHMA (Part 2) (2020) (0)
- Arterial hypertension (AH) and endothelial function (EF) in patients with COPD (2011) (0)
- Clinical status and systemic inflammation in COPD patients treated by magnetic stimulation of paravertebral ganglia (2013) (0)
- Observation of pregnant women (PW) after severe pneumonia (P) with influenza A/H1N1 virus infection in 2009-2010: Long-term results (2011) (0)
- The role of inflammatory biomarkers like precursors of COPD stability during long-term follow-up (2019) (0)
- BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP: POTENTIAL DIAGNOSTIC CRITERIA AND TREATMENT PRINCIPLES (2020) (0)
- Effects of nebivolol and ivabradine on the left ventricular diastolic function in patients (pts) with COPD and stable angina (2014) (0)
- Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)? (2016) (0)
- Ferritin versus D-dimer:comparison of prognostic roles in COVID-19 pneumonia (2021) (0)
- Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia (2013) (0)
- Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)? (2018) (0)
- Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level (2013) (0)
- "Many-armed” CD4: Why it is necessary to count blood CD4 at patient with severe community-acquired pneumonia (CAP)? (2015) (0)
- Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP) (2016) (0)
- Nosocomial pneumonia control programs: The most difficult questions (2012) (0)
- Influence of tiotropium bromide (TB) on the severity of clinical, functional symptoms and health-related quality of life (HRQL) in COPD patients (pts) (2011) (0)
- Diagnostic significance of questionnaire surveys for diagnosis of mental disorders in patients with chronic obstructive pulmonary disease (2016) (0)
- Artificial blood as a way to treat acute myocardial infarction (1998) (0)
- Continuing professional education – a priority direction of improving the professional competence of doctors: experience, achievements, problems and prospects. (2021) (0)
- THE WAYS TO IMPROVE TEACHING OF CLINICAL DISCIPLINES FOR ENGLISH-SPEAKING STUDENTS (2017) (0)
- [Hemosorption in the complex treatment of patients with bronchial asthma]. (1985) (0)
- Bronchial asthma in intensive care department: the factors influencing on exacerbation severity (2001) (0)
- Genetic testing for thrombophilia in case of unprovoked episode of pulmonary embolism (2021) (0)
- [Sorption methods in the complex treatment of patients with bronchial asthma]. (1988) (0)
- Pneumonia in patients on the background of blood cancer (2014) (0)
- Effect of respiratory pathology on the quality of life for patients, suffering from rheumatoid arthritis (2012) (0)
- Neutrophil-to-lymphocyte ratio in predicting prognosis and course of community community-acquired pneumonia in hospitalized patients. (2018) (0)
- Community-aquired pneumonia associated with coronavirus disease (COVID-19): determination of pathological process progression predictors by clinical and hemocoagulation parameters (2022) (0)
- Massive polyuria associated with severe COVID-19-related pneumonia complicated by pulmonary embolism (2023) (0)
- IDIOPATHIC PULMONARY FIBROSIS AND PROGRESSIVE PULMONARY FIBROSIS IN ADULTS: ADAPTED EVIDENCE-BASED CLINICAL GUIDELINE (DRAFT) (2023) (0)
- Lung vessels thrombosis in patients with lethal severe community-acquired pneumonia: electronic microscopies with 3D modeling (2019) (0)
- The comparison of diagnostic relevance of protein C, C-reactive protein and endothelin-1 for prediction of lung vessel thrombosis in patients with community-acquired pneumonia (2019) (0)
- The role of NT-proBNP in patients discharged after COVID-19 pneumonia (2022) (0)
- The role of endothelin-1 in hospitalized patients with community-acquired pneumonia (2019) (0)
- Adherence to ICS in pregnant with infectious exacerbations of asthma (IEA) (2017) (0)
- Episodes of asthma during pregnancy – link with a viral infection and treatment approaches. (2014) (0)
- Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization (2011) (0)
- Is hyaluronic acid (HA) a marker of effectiveness of anti-inflammatory therapy in COPD patients? (2013) (0)
- EFFECTS OF N-ACETYLCYSTEIN ON PROTEINAS-INHIBITORY SYSTEM WITH СHRONIC OBSTRUCTIVE PULMONARY DISEASE (2020) (0)
- New diagnostic possibilities for determining the nature of respiratory symptoms in patients with chronic obstructive pulmonary disease (2016) (0)
- Role of matrix metalloproteinase in predicting of COPD stability (2015) (0)
- Plasminogen activator inhibitor-1 (PAI-1) like the best mortality predictor of in the COVID-19-associated pneumonia (2022) (0)
- Carbon monoxide diffusing capacity (DLCO) in COVID-19 survivors versus idiopathic pulmonary fibrosis (IPF): the pathogenetic features (2021) (0)
- Diagnostics of disorders of mucociliary clearance in patients with chronic obstructive pulmonary disease by determining content of medium weight molecules in sputum. (2014) (0)
- Survival predictors of severe community-acquired pneumonia (CAP): Multivariate analysis of immunological and inflammatory parameters (2014) (0)
- What is the best biomarker of COPD stability (2015) (0)
- The role of spirometry and ?arbon monoxide diffusing capacity (DLCO) in the diagnosis of pulmonary function in patients after COVID-19 pneumonia (2021) (0)
- Laboratory investigation of sputum and mucociliary clearance (MCC) condition in patients with COPD (2011) (0)
- Features of mucous membrane changes of bronchial tree at patients with COPD (2011) (0)
- The relationship between dyspnea and detection of depression in COPD patients (pts) (2015) (0)
- CLINICAL PHENOTYPES OF COVID-19 PNEUMONIA: different phases of viral process or really different states? (2022) (0)
- Myocardial ischemia in patients (pts) with COPD and stable angina during 24-hour ambulatory Holter ECG monitoring (2015) (0)
- Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) (2015) (0)
- Effect of short-acting bronchodilators (BDs) on the severity of respiratory muscle (RM) strength in COPD patients (pts) (2013) (0)
- MORTALITY PREDICTORS IN COVID-19 PNEUMONIA: RESULTS OF LARGE ROC-ANALISIS (2022) (0)
- Medical staff attitude to vaccination against an influenza virus (2013) (0)
- Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients (2015) (0)
- ASTHMA 2020: NEW GLOBAL RESEARCH DATA (2021) (0)
- Influence of COVID-19 pneumonia on development of mental disorders (2021) (0)
- Myocardial dysfunction in patients (pts) after severe coronavirus disease (COVID-19) (2021) (0)
- The dynamics of dyspnea in patients (pts) with pneumonia on the background of SARS-CoV2 infection (2021) (0)
- COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level (2012) (0)
- Matrix metalloproteinase, hyaluronic acid and C-reactive protein: Are they really markers of lung obstruction at COPD but not cardiovascular comorbidity? (2015) (0)
This paper list is powered by the following services:
Other Resources About Tetyana Pertseva
What Schools Are Affiliated With Tetyana Pertseva?
Tetyana Pertseva is affiliated with the following schools:
